BioWorld

Sep. 7, 2005

View Archived Issues

EpiCept To Take Maxim In $136M Stock Buyout

Privately held pain drug firm EpiCept Corp. entered a deal to pay about $136 million in stock to take over Maxim Pharmaceuticals Inc., and the agreement is expected to close in the fourth quarter. (BioWorld Today) Read More

Cephalon Files For Clearance Of OraVescent Fentanyl Tablet

Read More

Chiron Turns Down Novartis' Buyout Offer At $40 Per Share

Read More

PDL's Stock Rises On Ularitide Phase II Data, Analyst Upgrade

Read More

Other News To Note

Read More